Yowza — 94 Utah Companies Make the Inc. 5000 List for 2024, with 64 Repeat Honorees
Between them, these 94 Utah-based firms had a 230% median growth rate, while 64 of the 94 firms were repeat honorees.
Park City, Utah-based EQV Ventures Acquisition Corp. has Raised $350 Million in an IPO Focused on Acquiring a "Going Concern" Through a SPAC Merger
In a surprise turn of events, a Utah-based startup with no operations completed an Initial Public Offering on the New York Stock Exchange earlier this month, generating $350 million in gross proceeds in the process.
According to a company news release published on 06 August 2024, Park City, Utah-based EQV
The Top 11 Utah-focused Monetary, Financial and/or Business News Nuggets from the Second Half of July 2024 that You Might have Missed
{AUTHOR'S NOTE: Clearly, not every news announcement deserves to be the top story of the day. Nevertheless, many news items are significant and should be acknowledged as such. And in this writeup, you'll find info about 11 Utah-based firms and eight separate executives that we feel
NEWS BRIEF: Utah's Green Dot Bank is Fined $44.0 Million by the U.S. Federal Reserve Board
Citing "... unfair and deceptive acts and practices in violation of Section 5(a)(1) of the FTC Act..." and "... a faulty consumer compliance risk management program ..." (from 2017 through 2022), the Federal Reserve also issued what appears to be a comprehensive Consent Order against Green Dot
But Wait, There's More: Utah-based Recursion Pharmaceuticals is Acquiring UK-based Exscientia for $688 Million in an All-Stock Deal
Early yesterday morning (Thursday, 08 August 2024), Salt Lake City, Utah-based Recursion Pharmaceuticals (NASDAQ:RXRX) announced that is "combining" with Oxford, England-based Exscientia (NASDAQ:EXAI) in an all-stock transaction that will create a global tech-enabled drug-development / drug-discovery powerhouse.
Under terms of the agreement disclosed in yesterday's
Creation of the World's First "Neuromap" by Utah-based Recursion Pharmaceuticals Triggers a $30 Million Payment from Roche and Genentech
Recursion breakthrough leads to new type of mapping the brain.
NEWS & ANALYSIS: Utah's R1 RCM has Boosted its Value by ~60% in Just One Month as it's Now Agreed to be Acquired in an All-Cash Deal at a Valuation of $8.9 Billion by TowerBrook and Clayton, Dubilier & Rice
Sometimes, the best decision is to "hold out for a better offer."